Source: Eur Respir J, 57 (3) 2004645; 10.1183/13993003.04645-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jakob Borchardt. Comment on: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis. Eur Respir J, 57 (3) 2004645; 10.1183/13993003.04645-2020

Member's Comments

No comment yet.

Related content which might interest you: Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (3) 2100283; 10.1183/13993003.00283-2021 Year: 2021 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Hyaluroman syntehase-2 over expression has impact in the evolution and on the prognosis of idiopathic pulmonary fibrosis patients Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 628s Year: 2006 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 347s Year: 2002 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016